AR108325A1 - Isoquinolin-3-il carboxamidas y preparación y uso de las mismas - Google Patents
Isoquinolin-3-il carboxamidas y preparación y uso de las mismasInfo
- Publication number
- AR108325A1 AR108325A1 ARP170101055A ARP170101055A AR108325A1 AR 108325 A1 AR108325 A1 AR 108325A1 AR P170101055 A ARP170101055 A AR P170101055A AR P170101055 A ARP170101055 A AR P170101055A AR 108325 A1 AR108325 A1 AR 108325A1
- Authority
- AR
- Argentina
- Prior art keywords
- unsubstituted
- alkylene
- optionally substituted
- group
- haloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Abstract
Se divulgan compuestos isoquinolina para tratar diversas enfermedades y patologías. Más específicamente, se refiere al uso de un compuesto isoquinolina o a análogos del mismo, en el tratamiento de trastornos caracterizados por la activación de la señalización de la vía de Wnt (por ejemplo, cáncer, proliferación celular anormal, angiogénesis, trastornos fibróticos, enfermedades óseas y de los cartílagos y osteoartritis), la modulación de eventos celulares mediados por la señalización de la vía de Wnt, así como enfermedades genéticas y condiciones / trastornos / enfermedades neurológicas debido a mutaciones o la desregulación de la vía de Wnt y/o de uno o más componentes de la señalización de Wnt. También se proveen métodos para tratar estados de enfermedad relacionados con Wnt. Reivindicación 1: Un compuesto o una sal farmacéuticamente aceptable del mismo, de la fórmula (1), en donde: R¹, R², R⁴ y R⁵ se seleccionan independientemente del grupo que consiste en H, haluro, amino, -(haloalquilo C₁₋₃) no sustituido y -(alquilo C₁₋₃) no sustituido; R³ es un heteroarilo de 5 miembros opcionalmente sustituido con 1 - 4 R⁴⁵; R⁶ se selecciona del grupo que consiste en -fenilo sustituido con 1 - 5 R³⁶, -(alquileno C₁₋₃)ₚ-piridinilo opcionalmente sustituido con 1 - 6 R³⁷ y un heteroarilo de 6 - 10 miembros opcionalmente sustituido con 1 - 6 R³⁷; en donde el carbonilo de la fórmula (1) está unido a un anillo aromático del heteroarilo; en donde el -(alquileno C₁₋₃) se sustituye opcionalmente con uno o más sustituyentes definidos en cualquier lugar de la presente; cada R³⁶ se selecciona independientemente del grupo que consiste en haluro, -(alquilo C₁₋₉) no sustituido, -(alquenilo C₂₋₉) no sustituido, -(alquinilo C₂₋₉) no sustituido, -(haloalquilo C₁₋₉) no sustituido, -XR⁴², -C(=O)N(R⁴⁷)₂, -(alquileno C₁₋₄)ₚ-N(R⁵⁰)₂, -(alquileno C₁₋₄)ₚ-heterociclilo opcionalmente sustituido con 1 - 10 R⁴³ y -(alquileno C₁₋₄)ₚ-carbociclilo opcionalmente sustituido con 1 - 12 R⁴⁴; en donde cada -(alquileno C₁₋₄) se sustituye opcionalmente, en forma independiente, con uno o más sustituyentes definidos en cualquier lugar de la presente; cada R³⁷ se selecciona independientemente del grupo que consiste en haluro, -(alquilo C₁₋₉) no sustituido, -(alquenilo C₂₋₉) no sustituido, -(alquinilo C₂₋₉) no sustituido, -(haloalquilo C₁₋₉) no sustituido, -XR⁴², -C(=O)N(R⁴⁷)₂, -(alquileno C₁₋₄)ₚ-N(R⁵⁰)₂, -(alquileno C₁₋₄)ₚ-heterociclilo opcionalmente sustituido con 1 - 10 R⁴³ y -(alquileno C₁₋₄)ₚ-carbociclilo opcionalmente sustituido con 1 - 12 R⁴⁴; en donde cada -(alquileno C₁₋₄) se sustituye opcionalmente, en forma independiente, con uno o más sustituyentes definidos en cualquier lugar de la presente; cada R³⁸ se selecciona independientemente del grupo que consisto en haluro, -(alquilo C₁₋₅) no sustituido, -(alquenilo C₂₋₅) no sustituido, -(alquinilo C₂₋₅) no sustituido, -(haloalquilo C₁₋₅) no sustituido, -CN y -(alquileno C₁₋₄)ₚ-carbociclilo opcionalmente sustituido con 1 - 12 R⁴⁴; en donde cada -(alquileno C₁₋₄) se sustituye opcionalmente, en forma independiente, con uno o más sustituyentes definidos en cualquier lugar de la presente; cada R³⁹ se selecciona independientemente del grupo que consiste en haluro, -(alquilo C₁₋₅) no sustituido, -(alquenilo C₂₋₅) no sustituido, -(alquinilo C₂₋₅) no sustituido, -(haloalquilo C₁₋₅) no sustituido, -CN y -(alquileno C₁₋₄)ₚ-carbociclilo opcionalmente sustituido con 1 - 12 R⁴⁴; en donde cada -(alquileno C₁₋₄) se sustituye opcionalmente, en forma independiente con uno o más sustituyentes definidos en cualquier lugar de la presente; cada R⁴⁰ se selecciona independientemente del grupo que consiste en haluro, -(alquilo C₁₋₅) no sustituido, -(alquenilo C₂₋₅) no sustituido, -(alquinilo C₂₋₅) no sustituido, -(haloalquilo C₁₋₅) no sustituido, -CN y -(alquileno C₁₋₄)ₚ-carbociclilo opcionalmente sustituido con 1 - 12 R⁴⁴; en donde cada -(alquileno C₁₋₄) se sustituye opcionalmente, en forma independiente con uno o más sustituyentes definidos en cualquier lugar de la presente; cada R⁴¹ se selecciona independientemente del grupo que consiste en haluro, -(alquilo C₁₋₅) no sustituido, -(alquenilo C₂₋₅) no sustituido, -(alquinilo C₂₋₅) no sustituido, -(haloalquilo C₁₋₅) no sustituido y -CN; cada R⁴² se selecciona independientemente del grupo que consiste en H, -(alquilo C₁₋₅) no sustituido, -(alquenilo C₂₋₅) no sustituido, -(alquinilo C₂₋₅) no sustituido, -(haloalquilo C₁₋₅) no sustituido, -(alquileno C₁₋₄)N(R⁴⁸)₂, -(alquileno C₁₋₄)ₚ-arilo opcionalmente sustituido con 1 - 10 R⁴⁶, -(alquileno C₁₋₄)ₚ-heterociclilo opcionalmente sustituido con 1 - 12 R⁴³ y -(alquileno C₁₋₄)ₚ-carbociclilo opcionalmente sustituido con 1 - 12 R⁴⁴; en donde cada -(alquileno C₁₋₄) se sustituye opcionalmente, en forma independiente, con uno o más sustituyentes definidos en cualquier lugar de la presente; cada R⁴³ se selecciona independientemente del grupo que consiste en haluro, -(alquilo C₁₋₅) no sustituido, -(alquenilo C₂₋₅) no sustituido, -(alquinilo C₂₋₅) no sustituido, -(haloalquilo C₁₋₅) no sustituido, -CN, -OH, -C(=O)R⁵¹, -N(R⁵⁰)₂ y -(alquileno C₁₋₄)ₚ-carbociclilo opcionalmente sustituido con 1 - 12 R⁴⁴; en donde cada -(alquileno C₁₋₄) se sustituye opcionalmente, en forma independiente, con uno o más sustituyentes definidos en cualquier lugar de la presente; cada R⁴⁴ se selecciona independientemente del grupo que consiste en haluro, -(alquilo C₁₋₅) no sustituido, -(alquenilo C₂₋₅) no sustituido, -(alquinilo C₂₋₅) no sustituido, -(haloalquilo C₁₋₅) no sustituido y -CN; cada R⁴⁵ se selecciona independientemente del grupo que consiste en haluro, -(alquilo C₁₋₉) no sustituido, -(alquenilo C₂₋₉) no sustituido, -(alquinilo C₂₋₉) no sustituido, -(haloalquilo C₁₋₉) no sustituido, -(alquileno C₁₋₄)ₚ-N(R⁴⁸)₂, -(alquileno C₁₋₄)ₚ-OR⁴⁹, -C(=O)N(R⁴⁸)₂, -(alquileno C₁₋₄)ₚ-heterociclilo opcionalmente sustituido con 1 - 10 R³⁸, -carbociclilo opcionalmente sustituido con 1 - 12 R³⁹; en donde cada -(alquileno C₁₋₄) se sustituye opcionalmente, en forma independiente, con uno o más sustituyentes definidos en cualquier lugar de la presente; alternativamente, dos R⁴⁵ adyacentes tomados juntos forman un anillo que se selecciona del grupo que consiste en -heterociclilo opcionalmente sustituido con 1 - 10 R⁴⁰ y -carbociclilo opcionalmente sustituido con 1 - 12 R⁴¹; cada R⁴⁶ se selecciona independientemente del grupo que consiste en -(alquilo C₁₋₅) no sustituido, -(alquenilo C₂₋₅) no sustituido, -(alquinilo C₂₋₅) no sustituido, -(haloalquilo C₁₋₅) no sustituido y -CN; cada R⁴⁷ se selecciona independientemente del grupo que consiste en H, -(alquilo C₁₋₅) no sustituido, -(alquenilo C₂₋₅) no sustituido, -(alquinilo C₂₋₅) no sustituido y -(haloalquilo C₁₋₅) no sustituido; cada R⁴⁸ se selecciona del grupo que consiste en H, -(alquilo C₁₋₅) no sustituido, -(alquenilo C₂₋₅) no sustituido, -(alquinilo C₂₋₅) no sustituido, -(haloalquilo C₁₋₅) no sustituido; cada R⁴⁹ se selecciona independientemente del grupo que consiste en H, -(alquilo C₁₋₅) no sustituido, -(alquenilo C₂₋₅) no sustituido, -(alquinilo C₂₋₅) no sustituido y -(haloalquilo C₁₋₅) no sustituido; cada R⁵⁰ se selecciona independientemente del grupo que consiste en H, -(alquilo C₁₋₅) no sustituido, -(alquenilo C₂₋₅) no sustituido, -(alquinilo C₂₋₅) no sustituido, -(haloalquilo C₁₋₅) no sustituido y -(alquileno C₁₋₄)N(R⁴⁸)₂; en donde el -(alquileno C₁₋₄) se sustituye opcionalmente con uno o más sustituyentes definidos en cualquier lugar de la presente; cada R⁵¹ es un heteroarilo opcionalmente sustituido con 1 - 6 R⁵²; cada R⁵² es un -heterociclilo opcionalmente sustituido con 1 - 10 R⁴⁶; cada X se selecciona del grupo que consiste en O, S y NR⁴⁸; y cada p es independientemente 0 ó 1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662328255P | 2016-04-27 | 2016-04-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR108325A1 true AR108325A1 (es) | 2018-08-08 |
Family
ID=60157337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170101055A AR108325A1 (es) | 2016-04-27 | 2017-04-26 | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
Country Status (28)
Country | Link |
---|---|
US (7) | US10106527B2 (es) |
EP (2) | EP3448386B1 (es) |
JP (1) | JP6993985B2 (es) |
KR (1) | KR102374844B1 (es) |
CN (1) | CN109310690B (es) |
AR (1) | AR108325A1 (es) |
AU (1) | AU2017258193B2 (es) |
CA (1) | CA3022002A1 (es) |
CL (2) | CL2018003065A1 (es) |
CO (1) | CO2018012299A2 (es) |
CY (1) | CY1124302T1 (es) |
DK (1) | DK3448386T3 (es) |
ES (1) | ES2865374T3 (es) |
HR (1) | HRP20210607T1 (es) |
HU (1) | HUE054103T2 (es) |
IL (1) | IL262470B (es) |
LT (1) | LT3448386T (es) |
MA (1) | MA43619B1 (es) |
MD (1) | MD3448386T2 (es) |
MX (1) | MX2018013174A (es) |
PE (1) | PE20190326A1 (es) |
PH (1) | PH12018502258A1 (es) |
PL (1) | PL3448386T3 (es) |
PT (1) | PT3448386T (es) |
RS (1) | RS61879B1 (es) |
SG (2) | SG10201914054SA (es) |
SI (1) | SI3448386T1 (es) |
WO (1) | WO2017189829A1 (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
AU2016348639B2 (en) | 2015-11-06 | 2022-09-08 | Samumed, Llc | Treatment of osteoarthritis |
EA201800367A1 (ru) | 2015-12-10 | 2019-02-28 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы лечения болезни хантингтона |
AR108325A1 (es) * | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
AR108326A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
TW201803869A (zh) | 2016-04-27 | 2018-02-01 | 健生藥品公司 | 作為RORγT調節劑之6-胺基吡啶-3-基噻唑 |
EP3601259B1 (en) | 2017-03-30 | 2022-02-23 | F. Hoffmann-La Roche AG | Isoquinolines as inhibitors of hpk1 |
CA3066224A1 (en) | 2017-06-05 | 2018-12-13 | Ptc Therapeutics Inc. | Compounds for treating huntington's disease |
CN111163838B (zh) | 2017-06-28 | 2023-03-28 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
MX2019015578A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
US10604514B2 (en) | 2017-10-19 | 2020-03-31 | Samumed, Llc | 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof |
US10413537B2 (en) | 2017-10-27 | 2019-09-17 | Samumed, Llc | 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof |
US10653688B2 (en) | 2017-10-27 | 2020-05-19 | Samumed, Llc | 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof |
US10703748B2 (en) | 2017-10-31 | 2020-07-07 | Samumed, Llc | Diazanaphthalen-3-yl carboxamides and preparation and use thereof |
WO2019191092A1 (en) | 2018-03-27 | 2019-10-03 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
JP2021528398A (ja) | 2018-06-18 | 2021-10-21 | ヤンセン ファーマシューティカ エヌ.ベー. | RORγTのモジュレーターとしての6−アミノピリジン−3−イルピラゾール |
US11345666B2 (en) | 2018-06-18 | 2022-05-31 | Janssen Pharmaceutica Nv | Phenyl and pyridinyl substituted imidazoles as modulators of RORγT |
CN112566901A (zh) | 2018-06-18 | 2021-03-26 | 詹森药业有限公司 | 作为RORγt的调节剂的苯基取代的吡唑类 |
ES2925473T3 (es) | 2018-06-18 | 2022-10-18 | Janssen Pharmaceutica Nv | Pirazoles de piridinilo como moduladores de RORyt |
SG11202012674PA (en) | 2018-06-27 | 2021-01-28 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for treating huntington's disease |
WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
WO2020150552A2 (en) | 2019-01-17 | 2020-07-23 | Samumed, Llc | Methods of treating cartilage disorders through inhibition of clk and dyrk |
WO2021004547A1 (en) * | 2019-07-11 | 2021-01-14 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of hpk1 |
WO2021007378A1 (en) * | 2019-07-11 | 2021-01-14 | Ptc Therapeutics, Inc. | Compounds for use in treating huntington's disease |
JPWO2021235293A1 (es) * | 2020-05-20 | 2021-11-25 | ||
CN117088876A (zh) * | 2020-10-28 | 2023-11-21 | 杭州阿诺生物医药科技有限公司 | 一种高活性Wnt通路抑制剂化合物 |
TW202321244A (zh) * | 2021-07-26 | 2023-06-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 一種Wnt通路抑制劑化合物 |
TW202334157A (zh) * | 2022-01-29 | 2023-09-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 一種Wnt通路抑制劑化合物 |
WO2024022365A1 (zh) * | 2022-07-28 | 2024-02-01 | 杭州阿诺生物医药科技有限公司 | 一种Wnt通路抑制剂化合物 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4164559A (en) | 1977-09-21 | 1979-08-14 | Cornell Research Foundation, Inc. | Collagen drug delivery device |
US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
DE19746287A1 (de) * | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
US6440102B1 (en) | 1998-07-23 | 2002-08-27 | Durect Corporation | Fluid transfer and diagnostic system for treating the inner ear |
DE19853299C2 (de) | 1998-11-19 | 2003-04-03 | Thomas Lenarz | Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs |
US6120484A (en) | 1999-02-17 | 2000-09-19 | Silverstein; Herbert | Otological implant for delivery of medicament and method of using same |
US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
US6648873B2 (en) | 2001-09-21 | 2003-11-18 | Durect Corp. | Aural catheter system including anchor balloon and balloon inflation device |
GB0310867D0 (en) | 2003-05-12 | 2003-06-18 | Novartis Ag | Organic compounds |
EP2256106B1 (en) | 2003-07-22 | 2015-05-06 | Astex Therapeutics Limited | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
US7008953B2 (en) | 2003-07-30 | 2006-03-07 | Agouron Pharmaceuticals, Inc. | 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
EP1861161A4 (en) | 2005-01-24 | 2012-05-16 | Neurosystec Corp | APPARATUS AND METHOD FOR DISPENSING THERAPEUTIC AND / OR OTHER AGENTS IN THE INTERNAL EAR AND OTHER FABRICS |
WO2007125405A2 (en) * | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
US8088793B2 (en) | 2007-08-15 | 2012-01-03 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
WO2009085226A2 (en) | 2007-12-21 | 2009-07-09 | Sirtris Pharmaceuticals, Inc. | Inhibitors of cdc2-like kinases (clks) and methods of use thereof |
UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
BR112012002942A2 (pt) | 2009-08-10 | 2015-10-13 | Epitherix Llc | indazóis como inibidores da trilha de sinalização de wnt/b-catenina e empregos terapêuticos destes. |
ES2835553T3 (es) | 2009-08-10 | 2021-06-22 | Biosplice Therapeutics Inc | Inhibidores de indazol de la vía de señalización de Wnt y sus usos terapéuticos |
US7998878B2 (en) | 2009-11-20 | 2011-08-16 | Eastman Kodak Company | Method for selective deposition and devices |
CA2986631C (en) | 2009-12-21 | 2020-06-02 | Samumed, Llc | 1h-pyrazolo[3,4-.beta.]pyridines and thereapeutic uses thereof |
US20130096119A1 (en) | 2010-03-31 | 2013-04-18 | Daniel Bur | Isoquinolin-3-Ylurea Derivatives |
TW201307292A (zh) * | 2010-12-17 | 2013-02-16 | Hoffmann La Roche | 經取代之6,6-稠合含氮雜環化合物及其用途 |
CN102558173B (zh) * | 2010-12-31 | 2015-05-20 | 广州源生医药科技有限公司 | 抑制wnt信号传导的化合物、组合物及其应用 |
MX341504B (es) * | 2011-09-14 | 2016-08-19 | Samumed Llc | Indazol-3-carboxamidas y su uso como inhibidores de la trayectoria de señalización de wnt/b-catenina. |
WO2013169793A2 (en) * | 2012-05-09 | 2013-11-14 | Ipierian, Inc. | Methods and compositions for tdp-43 proteinopathies |
US9557993B2 (en) | 2012-10-23 | 2017-01-31 | Analog Devices Global | Processor architecture and method for simplifying programming single instruction, multiple data within a register |
BR112016021626A2 (pt) | 2014-03-20 | 2018-05-15 | Samumed, Llc | indazol-3-carboxamidas 5-substituídas e preparação e uso das mesmas |
GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
AR108326A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
AR108325A1 (es) * | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
CN109937039A (zh) | 2016-09-30 | 2019-06-25 | 斯坦福国际研究院 | 用于癌症治疗的双重clk/cdk1抑制剂 |
US20220062240A1 (en) | 2018-06-26 | 2022-03-03 | Biosplice Therapeutics, Inc. | Methods of treating cancer using a clk inhibitor |
WO2020150545A1 (en) | 2019-01-17 | 2020-07-23 | Samumed, Llc | Pyrazole derivatives as modulators of the wnt/b-catenin signaling pathway |
-
2017
- 2017-04-26 AR ARP170101055A patent/AR108325A1/es unknown
- 2017-04-27 SI SI201730725T patent/SI3448386T1/sl unknown
- 2017-04-27 CN CN201780037225.6A patent/CN109310690B/zh active Active
- 2017-04-27 EP EP17790416.6A patent/EP3448386B1/en active Active
- 2017-04-27 MX MX2018013174A patent/MX2018013174A/es unknown
- 2017-04-27 EP EP21159576.4A patent/EP3892276A1/en active Pending
- 2017-04-27 JP JP2018556902A patent/JP6993985B2/ja active Active
- 2017-04-27 KR KR1020187034084A patent/KR102374844B1/ko active IP Right Grant
- 2017-04-27 SG SG10201914054SA patent/SG10201914054SA/en unknown
- 2017-04-27 ES ES17790416T patent/ES2865374T3/es active Active
- 2017-04-27 AU AU2017258193A patent/AU2017258193B2/en active Active
- 2017-04-27 PL PL17790416T patent/PL3448386T3/pl unknown
- 2017-04-27 HU HUE17790416A patent/HUE054103T2/hu unknown
- 2017-04-27 WO PCT/US2017/029805 patent/WO2017189829A1/en active Application Filing
- 2017-04-27 SG SG11201809301YA patent/SG11201809301YA/en unknown
- 2017-04-27 CA CA3022002A patent/CA3022002A1/en active Pending
- 2017-04-27 US US15/499,013 patent/US10106527B2/en active Active
- 2017-04-27 PT PT177904166T patent/PT3448386T/pt unknown
- 2017-04-27 MD MDE20190282T patent/MD3448386T2/ro unknown
- 2017-04-27 MA MA43619A patent/MA43619B1/fr unknown
- 2017-04-27 DK DK17790416.6T patent/DK3448386T3/da active
- 2017-04-27 PE PE2018002194A patent/PE20190326A1/es unknown
- 2017-04-27 RS RS20210466A patent/RS61879B1/sr unknown
- 2017-04-27 LT LTEP17790416.6T patent/LT3448386T/lt unknown
- 2017-12-06 US US15/833,917 patent/US9951048B1/en active Active
-
2018
- 2018-01-30 US US15/884,112 patent/US10100038B2/en active Active
- 2018-09-13 US US16/130,842 patent/US10544128B2/en active Active
- 2018-10-18 IL IL262470A patent/IL262470B/en unknown
- 2018-10-23 PH PH12018502258A patent/PH12018502258A1/en unknown
- 2018-10-26 CL CL2018003065A patent/CL2018003065A1/es unknown
- 2018-11-14 CO CONC2018/0012299A patent/CO2018012299A2/es unknown
-
2019
- 2019-05-16 CL CL2019001343A patent/CL2019001343A1/es unknown
- 2019-12-04 US US16/703,321 patent/US10947217B2/en active Active
-
2021
- 2021-01-22 US US17/155,577 patent/US11548872B2/en active Active
- 2021-04-16 HR HRP20210607TT patent/HRP20210607T1/hr unknown
- 2021-04-21 CY CY20211100344T patent/CY1124302T1/el unknown
-
2022
- 2022-11-18 US US17/990,133 patent/US20230286945A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR108325A1 (es) | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas | |
AR108326A1 (es) | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas | |
AR115993A2 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
RU2019119893A (ru) | Ингибиторы jak2 и alk2 и способы их использования | |
AR119651A1 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
AR109788A1 (es) | Compuestos de benzo[b]tiofeno como agonistas de sting | |
CY1118739T1 (el) | Ενωσεις αμφι(φθoρoαλκυλ)-1,4-βενζoδιαζεπινoνης ως αναστολεις toy notch | |
AR103833A1 (es) | Compuestos bicíclicos de sulfonamida cetona | |
EA201592126A1 (ru) | 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
AR095885A1 (es) | Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2 | |
EA201592199A1 (ru) | Производные бипиразола в качестве ингибиторов jak | |
EA201691302A1 (ru) | Новые гетероциклические соединения | |
SA515361086B1 (ar) | Fasn مركبات وتركيبات جديدة لتثبيط | |
AR103251A1 (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
AR089285A1 (es) | Derivados de betulina | |
AR089781A1 (es) | Fluorometil-5,6-dihidro-4h-[1,3]oxazinas | |
EA201592287A1 (ru) | Замещенные тетрагидрокарбазольные и карбазолкарбоксамидные соединения | |
EA201690012A1 (ru) | Карбазолкарбоксамидные соединения | |
AR094496A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
AR097435A1 (es) | 6-alquinilpiridinas | |
AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
AR100715A1 (es) | Derivados de alquilo de compuestos 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor | |
AR093408A1 (es) | Derivados de oxazolidin-2-ona-pirimidina |